JP2006509830A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006509830A5 JP2006509830A5 JP2004563716A JP2004563716A JP2006509830A5 JP 2006509830 A5 JP2006509830 A5 JP 2006509830A5 JP 2004563716 A JP2004563716 A JP 2004563716A JP 2004563716 A JP2004563716 A JP 2004563716A JP 2006509830 A5 JP2006509830 A5 JP 2006509830A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cell
- dendritic
- use according
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 36
- 206010028980 Neoplasm Diseases 0.000 claims 20
- 201000011510 cancer Diseases 0.000 claims 18
- 210000004443 dendritic cell Anatomy 0.000 claims 18
- 241000124008 Mammalia Species 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 102000004127 Cytokines Human genes 0.000 claims 7
- 108090000695 Cytokines Proteins 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 230000004927 fusion Effects 0.000 claims 6
- 208000009956 adenocarcinoma Diseases 0.000 claims 5
- 230000003902 lesion Effects 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 102000013462 Interleukin-12 Human genes 0.000 claims 4
- 108010065805 Interleukin-12 Proteins 0.000 claims 4
- 206010039491 Sarcoma Diseases 0.000 claims 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 4
- 230000003511 endothelial effect Effects 0.000 claims 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 4
- 230000028996 humoral immune response Effects 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 4
- 230000000735 allogeneic effect Effects 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 108700028369 Alleles Proteins 0.000 claims 2
- 201000003076 Angiosarcoma Diseases 0.000 claims 2
- 206010003571 Astrocytoma Diseases 0.000 claims 2
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000005243 Chondrosarcoma Diseases 0.000 claims 2
- 201000009047 Chordoma Diseases 0.000 claims 2
- 208000006332 Choriocarcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000009798 Craniopharyngioma Diseases 0.000 claims 2
- 206010014967 Ependymoma Diseases 0.000 claims 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 2
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 102000043129 MHC class I family Human genes 0.000 claims 2
- 108091054437 MHC class I family Proteins 0.000 claims 2
- 208000000172 Medulloblastoma Diseases 0.000 claims 2
- 206010027406 Mesothelioma Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 201000010133 Oligodendroglioma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000007641 Pinealoma Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 201000000582 Retinoblastoma Diseases 0.000 claims 2
- 201000010208 Seminoma Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 230000005867 T cell response Effects 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000014070 Vestibular schwannoma Diseases 0.000 claims 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 2
- 208000008383 Wilms tumor Diseases 0.000 claims 2
- 208000004064 acoustic neuroma Diseases 0.000 claims 2
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 2
- 230000007910 cell fusion Effects 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 2
- 208000024207 chronic leukemia Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 208000002445 cystadenocarcinoma Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 201000002222 hemangioblastoma Diseases 0.000 claims 2
- 210000005260 human cell Anatomy 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 206010024627 liposarcoma Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000012804 lymphangiosarcoma Diseases 0.000 claims 2
- 230000001926 lymphatic effect Effects 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 206010027191 meningioma Diseases 0.000 claims 2
- 208000001611 myxosarcoma Diseases 0.000 claims 2
- 201000008026 nephroblastoma Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 208000024724 pineal body neoplasm Diseases 0.000 claims 2
- 208000037244 polycythemia vera Diseases 0.000 claims 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 2
- 208000018964 sebaceous gland cancer Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 201000008759 sweat gland cancer Diseases 0.000 claims 2
- 201000008753 synovium neoplasm Diseases 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 241000283690 Bos taurus Species 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- 241000283707 Capra Species 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 241000699800 Cricetinae Species 0.000 claims 1
- 241000283086 Equidae Species 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 241000287828 Gallus gallus Species 0.000 claims 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 241000700159 Rattus Species 0.000 claims 1
- 241000282887 Suidae Species 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 235000013330 chicken meat Nutrition 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 208000030399 gastrointestinal polyp Diseases 0.000 claims 1
- 102000054766 genetic haplotypes Human genes 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- 230000000415 inactivating effect Effects 0.000 claims 1
- 230000002779 inactivation Effects 0.000 claims 1
- 229940117681 interleukin-12 Drugs 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 208000025189 neoplasm of testis Diseases 0.000 claims 1
- 210000003757 neuroblast Anatomy 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/320,779 US20040115224A1 (en) | 2002-12-16 | 2002-12-16 | Preparation and administration of hybrid cell vaccines for the prevention of cancer |
| PCT/US2003/040284 WO2004057968A1 (en) | 2002-12-16 | 2003-12-16 | Preparation and administration of hybrid cell vaccines for the prevention of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006509830A JP2006509830A (ja) | 2006-03-23 |
| JP2006509830A5 true JP2006509830A5 (enExample) | 2007-02-08 |
Family
ID=32506941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004563716A Pending JP2006509830A (ja) | 2002-12-16 | 2003-12-16 | 癌予防用ハイブリッド細胞ワクチンの調製および投与 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20040115224A1 (enExample) |
| EP (1) | EP1583424A4 (enExample) |
| JP (1) | JP2006509830A (enExample) |
| AU (1) | AU2003301023A1 (enExample) |
| CA (1) | CA2508209A1 (enExample) |
| IL (1) | IL169124A0 (enExample) |
| WO (1) | WO2004057968A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL155514A0 (en) * | 2000-10-20 | 2003-11-23 | Tsuneya Ohno | Fusion cells and cytokine compositions for treatment of disease |
| US20050180951A1 (en) * | 2004-02-12 | 2005-08-18 | Tsuneya Ohno | Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer |
| JP2007528375A (ja) * | 2004-03-02 | 2007-10-11 | 典也 大野 | 癌の治療および予防用雑種細胞ワクチンの方法および組成物 |
| US8772046B2 (en) | 2007-02-06 | 2014-07-08 | Brandeis University | Manipulation of fluids and reactions in microfluidic systems |
| WO2008130623A1 (en) | 2007-04-19 | 2008-10-30 | Brandeis University | Manipulation of fluids, fluid components and reactions in microfluidic systems |
| CA2676808C (en) * | 2007-04-27 | 2016-08-02 | Bavarian Nordic A/S | Induction of dendritic cell development with macrophage-colony stimulating factor (m-csf) |
| US9695397B2 (en) * | 2008-10-01 | 2017-07-04 | Immunovative Therapies Ltd. | Th1 vaccination priming for active immunotherapy |
| WO2010111231A1 (en) | 2009-03-23 | 2010-09-30 | Raindance Technologies, Inc. | Manipulation of microfluidic droplets |
| JP2022542745A (ja) * | 2019-05-27 | 2022-10-07 | 錦高キャピタル株式会社 | 樹状細胞ベースの癌ワクチン及びその調製方法 |
| US20240002798A1 (en) * | 2020-11-17 | 2024-01-04 | Research & Business Foundation Sungkyunkwan University | Method for preparing immunogenicity-enhanced cd103+ fcgr3+ dendritic cell by treatment with interleukin-33 and pharmaceutical composition comprising same dendritic cell for cancer immunotherapy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU85919A1 (fr) * | 1984-06-07 | 1986-01-14 | Marginvest Sa Holding | Procede de preparation d'un agent absorbant et adsorbant,et agent absorbant et adsorbant ainsi obtenu |
| US5772995A (en) * | 1994-07-18 | 1998-06-30 | Sidney Kimmel Cancer Center | Compositions and methods for enhanced tumor cell immunity in vivo |
| US20020041868A1 (en) * | 1997-04-15 | 2002-04-11 | Charles Nicolette | Cell fusions and methods of making and using the same |
| DE69839215T2 (de) * | 1997-04-15 | 2009-03-19 | Dana-Farber Cancer Institute, Inc., Boston | Dendritische zellhybride |
| JP5054875B2 (ja) * | 2000-02-11 | 2012-10-24 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 樹状細胞ハイブリッドによって活性化される細胞傷害性ｔリンパ球 |
| IL155514A0 (en) * | 2000-10-20 | 2003-11-23 | Tsuneya Ohno | Fusion cells and cytokine compositions for treatment of disease |
-
2002
- 2002-12-16 US US10/320,779 patent/US20040115224A1/en not_active Abandoned
-
2003
- 2003-12-16 EP EP03814133A patent/EP1583424A4/en not_active Withdrawn
- 2003-12-16 JP JP2004563716A patent/JP2006509830A/ja active Pending
- 2003-12-16 WO PCT/US2003/040284 patent/WO2004057968A1/en not_active Ceased
- 2003-12-16 CA CA002508209A patent/CA2508209A1/en not_active Abandoned
- 2003-12-16 AU AU2003301023A patent/AU2003301023A1/en not_active Abandoned
-
2005
- 2005-06-09 IL IL169124A patent/IL169124A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | The role of NK cells and CD39 in the immunological control of tumor metastases | |
| Ganguly et al. | Canine transmissible venereal tumour: a review | |
| Mason et al. | Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy | |
| Hamouda et al. | Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4-1BBL induces systemic anti-tumor immunity | |
| Mattarollo et al. | Transient Foxp3+ regulatory T‐cell depletion enhances therapeutic anticancer vaccination targeting the immune‐stimulatory properties of NKT cells | |
| Lin et al. | Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies | |
| JP2006509830A5 (enExample) | ||
| US11254941B2 (en) | RNA nanostructures and methods of making and using RNA nanostructures | |
| CN109073637A (zh) | 用于预测蛋白质或蛋白质片段用于免疫治疗的有用性的方法 | |
| Zhu et al. | Remolding the tumor microenvironment by bacteria augments adoptive T cell therapy in advanced-stage solid tumors | |
| CN102753188A (zh) | 治疗脑瘤的方法 | |
| Lu et al. | Design of Light‐Activated Nanoplatform through boosting “eat me” signals for improved CD47‐blocking immunotherapy | |
| JP2009541333A (ja) | 修飾リボヌクレアーゼ | |
| KR20160089356A (ko) | 자가 종양 백신 및 방법 | |
| Den Otter et al. | Treatment of transmissible venereal tumors in dogs with intratumoral interleukin-2 (IL-2). A pilot study | |
| Tian et al. | Programing immunogenic cell death in breast tumors with designer DNA frameworks | |
| Lee et al. | Nano-assembly of a chemically tailored Cas9 ribonucleoprotein for in vivo gene editing and Cancer immunotherapy | |
| Jensen et al. | An in situ depot for the sustained release of a TLR7/8 agonist in combination with a TGFβ inhibitor promotes anti-tumor immune responses | |
| JP2010540681A (ja) | リボヌクレアーゼに基づく治療のための組成物及び方法 | |
| Thotathil et al. | Early experience with novel immunomodulators for cancer treatment | |
| Chen et al. | Thermosensitive hydrogel delivery of BCG lysates and tumor antigens: A novel strategy for melanoma immunoprevention and therapeutics | |
| US20170118965A1 (en) | Humanized mouse models and uses thereof | |
| TW202304486A (zh) | 福涅拉氏菌屬細胞外囊泡製劑 | |
| Miller et al. | Targeted TLR9 Agonist Elicits Effective Antitumor Immunity against Spontaneously Arising Breast Tumors | |
| Carreira et al. | Nanomedicines as multifunctional modulators of melanoma immune microenvironment |